 |
| WWIO Presents/Exhibits in NYC CNAB Files Landmark Patents |
|
 Hot Stock to Watch
|
Company: Wowio Inc (OTCBB: WWIO)
|
End of Day:
Price: 0.10
Change (%): + 0.01 (11.11)
Volume: 5,602 |
 |
WOWIO Presenting At Firerock Conference In NYC
WEST HOLLYWOOD, CA / ACCESSWIRE / October 28, 2014 / WOWIO, Inc. (OTCBB:WWIO), a digital media company with a patented process for inserting ads into eBooks, a mobile eBook distribution platform, and a proprietary mobile ad network, today announced that the company´s CEO, Brian Altounian, will present at the Firerock Conference in New York today, October 28 at 2PM EST.
FireRock Capital is a diversified financial services firm headquartered in New York City with offices in Los Angeles and Israel. The company´s annual micro-cap conference is an invitation only event that attracts hundreds of high net worth investors and financial leaders. This full day conference will also include panels comprised of top dealmakers as well as the leadership of FireRock´s portfolio companies.
Continue Reading
|
 Yesterday's Top Performer
|
Company: United Cannabis Corp. (OTCQB: CNAB)
|
End of Day:
Price: 0.85
Change (%): + 0.20 (30.77)
Volume: 127,796 |
 |
United Cannabis Corp. Files for Patents on Unique Combinations of Pharmaceutically Active Cannabinoids
Patents Relate to Company´s Proprietary Prana Bio Nutrient Medicinals Targeting Disorders of the Nervous System, Immune System and Cancer
Denver, CO / ACCESSWIRE / October 28, 2014 / United Cannabis Corp. (OTCBB: CNAB) (the "Company" or "United Cannabis") today announced that it has filed for provisional patents related to the unique combinations of pharmaceutically active cannabinoids used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office.
Using data derived from preclinical and clinical studies, United Cannabis´ research team has identified unique ratios and specifications of cannabinoids that can be used to target the underlying mechanisms of disorders such as PTSD, neuropathy and breast cancer.
Continue Reading |
Other Small Cap News
|
Company: Green Innovations Ltd. (OTCQB/BB: GNIN)
|
Green Innovations Signs, Wins Initial Order From 250-Store ShopRite; Wakefern's Subsidiary ShopRite to Boost GNIN's NE US Footprint
CAPE CORAL, FL--(Marketwired - Oct 28, 2014) - Green Innovations Ltd. (OTCQB/BB: GNIN) today announced that it has signed ShopRite supermarkets, and received its first purchase order, for its line of natural consumer paper products. New Jersey-based ShopRite has over 250 supermarkets in the northeast US, and is the largest retailer-owned cooperative in the US and the largest employer in New Jersey.
ShopRite is a subsidiary of New Jersey-based Wakefern Food Corporation. Wakefern and ShopRite together employ more than 50,000 people throughout New Jersey, New York, Connecticut, Pennsylvania, Delaware and Maryland. Founded in Keasbey, New Jersey in 1946, Wakefern also owns and operates PriceRite, a supermarket chain in the northeast US with over 50 stores.
Continue Reading
|
Company: Regen BioPharma Inc. (OTCBB: RGBP)
|
Regen BioPharma's Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Company Scientist Notes That One of the Major Side Effects Is the Destruction of Blood Vessels Leading to Internal Bleeding Which May Be Mitigated by Immunotherapeutic "Cocktail"
SAN DIEGO, CA--(Marketwired - Oct 28, 2014) - Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body's own immune system to identify and fight off these potentially fatal conditions.
Continue Reading |
Market News
|
By Steve Liesman: CNBC
|
Market pushes back Fed rate hike expectations: Survey
A month of worrisome headlines-from gathering weakness in Europe to the spread of Ebola to U.S. shores-has markets believing in a more dovish Federal Reserve, according to the latest CNBC Fed Survey.
As the Fed begins its two-day meeting Tuesday, the survey of 39 money managers, economists and advisors shows market expectations have been pushed out for the first Fed's rate hike and how quickly rates will rise. Respondents now forecast, on average, the first rate hike in July 2015, a month later than the September survey. Instead of reaching 0.98 basis points, the average respondent now sees the Fed hiking to 0.89 basis points by the end of next year.
"The global economy slowing down (particularly Europe along with their sovereign debt issues)... is the biggest risk to financial markets,'' Scott Wren of Wells Fargo Advisors wrote in response to the survey. "The biggest potential surprise for 2015 is that the Fed does not hike the target rate all year.''
Continue Reading
|
By Peter Schacknow: CNBC
|
Early Movers: DD, PFE, AET, TWTR, MSG, WMT & more
Check out which companies are making headlines before the bell:
DuPont - The chemical maker earned an adjusted 54 cents per share for the third quarter, beating estimates by a penny, but revenue was slightly short of consensus. DuPont said its profit margins improved in five of seven businesses, but it also noted it expects sluggish fourth quarter growth in the global economy, and further currency headwinds that will affect its agriculture business.
Pfizer- The pharmaceutical company beat estimates by 2 cents with adjusted quarterly profit of 57 cents per share, with revenue also above forecasts. Pfizer also narrowed its earnings forecast for the full year, as it evaluates the impact of increased generic competition and its efforts to develop new treatments.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
